In Thursday’s trading session, the shares of a company engaged in the production and marketing of pharmaceutical products surged by 1% to Rs. 155.44 on NSE, after Black Rock Financial Services Pvt. Ltd. bought stake in the company through an open market transaction on NSE.
At 12:05 p.m., the shares of Vaishali Pharma Limited were trading in the green at Rs. 154.48, up by 0.4 percent, compared to its previous closing price of Rs. 153.91, with a market cap of Rs. 163.5 crores.
What’s the News:
According to the 31st July bulk deal data available with the NSE, the domestic investor Black Rock Financial Services Pvt. Ltd. bought 92,612 equity shares in Vaishali Pharma, at an average price of Rs. 155.31 per share, resulting in a total transaction value of nearly Rs. 1.43 crore.
However, on the seller side, Eldorado Biotech Pvt Ltd offloaded the same number of shares at a marginally lower average price of Rs. 155.29.
Financials:
The company experienced significant growth in its revenue from operations, showing a year-on-year rise of nearly 6.8 percent from Rs. 26.3 crore in Q4 FY22-23 to Rs. 32.4 crore in Q4 FY23-24.
However, its net profit declined during the same period from a profit of Rs. 0.44 crore to a loss of Rs. 4.7 crore.
Stock performance:
The shares of Vaishali Pharma delivered nearly positive returns of nearly 9.5 percent in one year, but have given around 18.4 percent of negative returns year-to-date.
About the company:
Incorporated in 2008, Vaishali Pharma Limited is primarily engaged in the marketing of a diverse range of pharmaceutical products including active pharmaceutical ingredients (APIs), formulations, surgical products, veterinary supplements, herbal items, nutraceuticals, and oncology products. Their portfolio serves both human and animal healthcare needs.
With a domestic presence in Maharashtra, the company has expanded globally through partnerships in the Democratic Republic of Congo, Kenya, and Russia.
Written by Shivani Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
